Clinical trials: Relapsing Remitting Multiple Sclerosis RRMS
Relapsing-Remitting Multiple Sclerosis
A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
To look at the ability of LY2127399 to reduce magnetic resonance imaging (MRI) lesions at 12, 16, 20, and 24 weeks compared to placebo.
- Trial name
- NCT00882999
- Testing
- LY2127399
- Where
- 63 sites in United States, Bulgaria and 11 more
- Volunteers
- 245 people
- Sponsor
- Eli Lilly and Company
Multiple Sclerosis
Safety and Efficacy of Orally Administered Laquinimod Versus Placebo for Treatment of Relapsing Remitting Multiple Sclerosis (RRMS)
Determination the efficacy of daily oral treatment with laquinimod 0.6 mg capsules as compared to placebo in subjects with Relapsing Remitting Multiple Sclerosis (RRMS).
- Trial name
- ALLEGRO (NCT00509145)
- Testing
- Laquinimod
- Where
- 144 sites in United States, Austria and 22 more
- Volunteers
- 1,106 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Multiple Sclerosis, Relapsing-Remitting
A Cooperative Clinical Study of Abatacept in Multiple Sclerosis
The ACCLAIM study is testing whether the medication "abatacept" can be of benefit to patients with relapsing-remitting multiple sclerosis (MS). Although abatacept is an investigational medication for MS, it is not a new drug.
- Trial name
- ACCLAIM (NCT01116427)
- Testing
- abatacept
- Where
- 21 sites in United States, Canada
- Volunteers
- 65 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Relapsing Remitting Multiple Sclerosis
A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2
The objectives of this study are to evaluate the utility of two gastrointestinal (GI) symptom scales (Individual GI Symptom and Impact Scale {IGISIS} and Global GI Symptom and Impact Scale {GGISIS}) in assessing GI tolerability…
- Trial name
- NCT03093324
- Testing
- ALKS 8700, Dimethyl Fumarate
- Where
- 67 sites in United States, Germany and 1 more
- Volunteers
- 506 people
- Sponsor
- Biogen
Relapsing-Remitting Multiple Sclerosis (RRMS)
MRI Trial to exPlore the efficAcy and Safety of IMU-838 in Relapsing Remitting Multiple Sclerosis (EMPhASIS)
This is a Phase 2 multicenter, double-blind, placebo-controlled, randomized, parallel-group trial to assess the efficacy and safety of 2 once-daily oral doses of IMU-838 (vidofludimus calcium), a small molecule inhibitor of…
- Trial name
- EMPhASIS (NCT03846219)
- Testing
- IMU-838 (30 mg/day), IMU-838 (45 mg/day), IMU-838 (10 mg/day)
- Where
- 38 sites in Bulgaria, Poland and 2 more
- Volunteers
- 210 people
- Sponsor
- Immunic AG
Relapsing-Remitting Multiple Sclerosis (RRMS)
Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Natalizumab
The primary objective of the study is to evaluate the effects of treatment with daclizumab on the proportion of participants relapse-free at 6 months in Relapsing-Remitting Multiple Sclerosis (RRMS) participants, who switched…
- Trial name
- SUSTAIN (NCT02881567)
- Testing
- Daclizumab
- Where
- 11 sites in United States, Canada and 3 more
- Volunteers
- 41 people
- Sponsor
- Biogen
Multiple Sclerosis, Relapsing-Remitting
A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis
This is a phase II, multicenter, randomized, parallel-group, partially blinded, placebo and Avonex (interferon beta-1a) controlled dose finding study to evaluate the efficacy as measured by brain MRI lesions, and safety of 2 dose…
- Trial name
- NCT00676715
- Testing
- Ocrelizumab, Avonex
- Where
- 84 sites in United States, Belgium and 16 more
- Volunteers
- 220 people
- Sponsor
- Genentech, Inc.
Multiple Sclerosis
Rebif Advanced Magnetic Resonance Imaging (MRI) and Immunology Pilot Trial
The purpose of this trial is to evaluate the effects of Rebif® 44 mcg subcutaneous (sc) three times a week (tiw) on a) remyelination/demyelination, b) lesion and brain volume, c) central nervous system (CNS) iron deposition, and…
- Trial name
- NCT01085318
- Testing
- Rebif
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- EMD Serono
Multiple Sclerosis, Relapsing-Remitting
Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS)
This is a prospective, multicenter, open-label, single-arm, phase 3b study which evaluates effectiveness and safety of ocrelizumab in participants with early stage RRMS.
- Trial name
- NCT03085810
- Testing
- Ocrelizumab
- Where
- 193 sites in United States, Argentina and 27 more
- Volunteers
- 1,225 people
- Sponsor
- Hoffmann-La Roche
Multiple Sclerosis, Relapsing-Remitting
A Safety and Efficacy Study of Oral Cladribine in Subjects With Relapsing-remitting Multiple Sclerosis (RRMS)
The purpose of the study is to determine if cladribine tablets are a safe and effective treatment for relapsing-remitting multiple sclerosis (RRMS).
- Trial name
- CLARITY (NCT00213135)
- Testing
- Cladribine 5.25 mg/kg, Cladribine 3.5 mg/kg
- Volunteers
- 1,326 people
- Sponsor
- EMD Serono
Multiple Sclerosis, Relapsing-Remitting
Rehabilitation Study in MS Patients
Studying the effectiveness of a functional rehabilitation protocol (FRP) in early Relapsing Remitting Multiple Sclerosis (RRMS) patients treated with Betaferon by comparing the physical ability of patients with and without FRP.
- Trial name
- NCT00780455
- Testing
- Interferon beta-1b, FRP within 15 days after randomization, Interferon beta-1b, FRP about 6 weeks after randomization
- Where
- 10 sites in France
- Volunteers
- 4 people
- Sponsor
- Bayer
Relapsing-Remitting Multiple Sclerosis (RRMS)
Efficacy and Safety of the Biosimilar Natalizumab PB006 in Comparison to Tysabri®
This is a multi-center, randomized, parallel arm, double-blind study with a total duration of subjects' participation of 48 weeks.
- Trial name
- Antelope (NCT04115488)
- Testing
- Intravenous (IV) infusions
- Where
- 48 sites in Belarus, Croatia and 5 more
- Volunteers
- 265 people
- Sponsor
- Polpharma Biologics S.A.
Relapsing-remitting Multiple Sclerosis
A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)
This double-blind, double-dummy study will evaluate the safety and efficacy of ocrelizumab compared with fingolimod in children and adolescents with RRMS aged between 10 and < 18 years over a flexible duration.
- Trial name
- Operetta 2 (NCT05123703)
- Testing
- Ocrelizumab, Fingolimod
- Where
- 71 sites in United States, Argentina and 23 more
- Volunteers
- 188 people
- Sponsor
- Hoffmann-La Roche
Relapsing Remitting Multiple Sclerosis (RRMS)
RNF and Betaseron® Tolerability Study
To evaluate the tolerability of a new formulation of rebif and Betaseron in subjects with relapsing-remitting multiple sclerosis (RRMS) by comparing the mean change in injection site pain scores from pre-injection to 30 minutes…
- Trial name
- REFORMS (NCT00428584)
- Testing
- New Formulation of rebif - human interferon beta-1a, Interferon beta -1b
- Where
- United States
- Volunteers
- 129 people
- Sponsor
- EMD Serono
Multiple Sclerosis
Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms
The purpose of this pilot study is to evaluate, by means of a specific cognitive test battery (Brief Repeatable Battery and Delis-Kaplan Executive Function System scale), the slowing/reduction of cognitive dysfunction progression…
- Trial name
- Cognition (NCT01333501)
- Testing
- Fingolimod, Interferon beta 1b
- Where
- 26 sites in Germany, Italy
- Volunteers
- 151 people
- Sponsor
- Novartis Pharmaceuticals
Depression, Relapsing-remitting Multiple Sclerosis
Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression
This is a prospective, multi-center, open-label study in Relapsing-remitting Multiple Sclerosis (RRMS) patients with mild to moderate depression treated with selected serotonin reuptake inhibitors (SSRI) or serotonin and…
- Trial name
- REGAIN (NCT01436643)
- Testing
- Venlafaxine, Fluoxetine, Citalopram
- Where
- 25 sites in Germany
- Volunteers
- 54 people
- Sponsor
- Novartis Pharmaceuticals
Relapsing-Remitting Multiple Sclerosis
Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
The main objectives of Part 1 are as follows: To evaluate the safety, tolerability, and efficacy of BG00012 in pediatric participants with RRMS, as compared with a disease-modifying treatment and to assess health outcomes and…
- Trial name
- CONNECT (NCT02283853)
- Testing
- dimethyl fumarate, Interferon β-1a
- Where
- 62 sites in United States, Belgium and 16 more
- Volunteers
- 156 people
- Sponsor
- Biogen
Multiple Sclerosis
Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase
This study assessed the safety, tolerability, and efficacy of 2 doses of oral fingolimod versus interferon β-1a to reduce the frequency of relapses in patients with relapsing-remitting multiple sclerosis.
- Trial name
- TRANSFORMS (NCT00340834)
- Testing
- Fingolimod 1.25 mg, Fingolimod 0.5 mg, Interferon β-1a 30 µg
- Where
- 170 sites in United States, Argentina and 16 more
- Volunteers
- 1,292 people
- Sponsor
- Novartis
Relapsing Remitting Multiple Sclerosis
A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo
The study is designed to assess the efficacy of Glatiramer Acetate (GA) injection 40 mg administered three times a week compared to placebo in subjects with RRMS, as measured by the number of confirmed relapses during the 12…
- Trial name
- GALA (NCT01067521)
- Testing
- Glatiramer acetate (GA)
- Where
- 176 sites in United States, Bulgaria and 15 more
- Volunteers
- 1,404 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Relapsing-Remitting Multiple Sclerosis
Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants
The primary objective of this study is to assess the effect of natalizumab compared to fingolimod on the evolution of new on-treatment T1-gadolinium-enhancing (Gd+) lesions to persistent black holes (PBH) over 52 weeks.
- Trial name
- REVEAL (NCT02342704)
- Testing
- natalizumab, fingolimod
- Where
- 42 sites in United States, Australia and 7 more
- Volunteers
- 111 people, healthy volunteers welcome
- Sponsor
- Biogen